arrow_back Back to App

Increased funding for research and treatment of blood disorders, including sickle cell disease.

This act increases funding for research, surveillance, prevention, and treatment programs for sickle cell disease and other inherited blood disorders. This means more money will be allocated to combat these conditions, potentially improving access to care and innovative therapies for affected individuals.
Key points
Annual funding for blood disorder programs increased from $4.455 million to $8.205 million for fiscal years 2024-2028.
Expanded funding options to include grants and cooperative agreements, in addition to existing contracts, for research and treatment.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3884
Sponsor: Rep. Burgess, Michael C. [R-TX-26]
Process start date: 2023-06-07
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3884.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-07.

What are the main provisions?

Key points include:

  • Annual funding for blood disorder programs increased from $4.455 million to $8.205 million for fiscal years 2024-2028.
  • Expanded funding options to include grants and cooperative agreements, in addition to existing contracts, for research and treatment.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Burgess, Michael C. [R-TX-26].

What is the latest detailed status?

The latest detailed status is: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5578)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health